ANIX Stock Overview
A clinical-stage biotechnology company, focuses on the treatment and prevention of cancer.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Anixa Biosciences, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$3.32 |
52 Week High | US$5.13 |
52 Week Low | US$2.15 |
Beta | 0.87 |
11 Month Change | 7.44% |
3 Month Change | 27.20% |
1 Year Change | -7.00% |
33 Year Change | -31.12% |
5 Year Change | -23.33% |
Change since IPO | -93.19% |
Recent News & Updates
Recent updates
We're Not Very Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Rate
Sep 12We're Hopeful That Anixa Biosciences (NASDAQ:ANIX) Will Use Its Cash Wisely
May 23We're Not Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn
Jan 19We Think Anixa Biosciences (NASDAQ:ANIX) Can Easily Afford To Drive Business Growth
Oct 06Is There An Opportunity With Anixa Biosciences, Inc.'s (NASDAQ:ANIX) 41% Undervaluation?
Apr 27Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 36%?
Jan 13We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow
Sep 26Anixa adds 11% after dosing initiation in CAR-T ovarian cancer trial
Aug 15Anixa to get additional US patent linked to breast cancer vaccine technology
Jul 21Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans
Jun 13Anixa: Making Sense Of A Bullish Move Up In Bearish Biotech Times
May 11We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow
Feb 24Companies Like Anixa Biosciences (NASDAQ:ANIX) Can Afford To Invest In Growth
Oct 28Our First Look At Anixa Biosciences
Sep 23Here's Why We're Not At All Concerned With Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation
Jun 12OntoChem assigns Anixa covid-19 drug discovery project to MolGenie
May 07Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans
Jan 13Anixa Biosciences, Cleveland Clinic in ovarian cancer vaccine pact
Dec 01Shareholder Returns
ANIX | US Biotechs | US Market | |
---|---|---|---|
7D | -1.2% | 1.3% | 0.3% |
1Y | -7.0% | 16.5% | 21.7% |
Return vs Industry: ANIX underperformed the US Biotechs industry which returned 16.5% over the past year.
Return vs Market: ANIX underperformed the US Market which returned 21.7% over the past year.
Price Volatility
ANIX volatility | |
---|---|
ANIX Average Weekly Movement | 9.8% |
Biotechs Industry Average Movement | 10.4% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 15.1% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ANIX's share price has been volatile over the past 3 months.
Volatility Over Time: ANIX's weekly volatility (10%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1982 | 5 | Amit Kumar | www.anixa.com |
Anixa Biosciences, Inc., a clinical-stage biotechnology company, focuses on the treatment and prevention of cancer. Its therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR- T, known as chimeric endocrine receptor T-cell (CER-T) technology. The company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer – primarily triple negative breast cancer (TNBC), the lethal form of the disease, as well as a vaccine to prevent ovarian cancer.
Anixa Biosciences, Inc. Fundamentals Summary
ANIX fundamental statistics | |
---|---|
Market cap | US$99.43m |
Earnings (TTM) | -US$12.36m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-8.6x
P/E RatioIs ANIX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ANIX income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$12.36m |
Earnings | -US$12.36m |
Last Reported Earnings
Jul 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.38 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did ANIX perform over the long term?
See historical performance and comparison